fep blue glp-1 coverage 2025 These are the 2027 REQUIREMENTS for Obesity Management in FEHB simplified by ChatGPT Fep Blue Cross Blue Sheils

Glucagon agonism in the treatment of metabolic diseases including type 2 diabetes mellitus and obesity

Im working out

This is highly unsafe

The researchers noted that glucagon and GLP-1 can produce positive chronotropic and positive inotropic effects on the heart, but analyzed that the magnitude of the increase was similar to levels reported for existing GLP-1 receptor agonists

These are listed in order of priority based on deficiency prevalence and health impact

Common injection sites include: Abdomen Thigh Upper arm Safety Considerations and Side Effects GLP-1 Safety Profile Common Side Effects: Gastrointestinal issues (nausea, vomiting, diarrhea) Reduced appetite Headache Fatigue Serious but Rare: Pancreatitis Gallbladder problems Kidney issues Thyroid tumors (in animal studies